Tempus AI (TEM) announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality.
Claim 30% Off TipRanks
New trading tool for TEM bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI announces 10 abstracts accepted for presentation at 2025 ASCO meeting
- Tempus AI Stock (TEM) Could See ‘Tesla or Nvidia-Type Inflection,’ Claims Short Seller
- Cathie Wood’s ARK Investment bought 251K shares of Tempus AI today
- AI Daily: Nvidia suppliers accelerate production of Blackwell AI server racks
- Tempus AI down 3% after Spruce Point short report